Blab AI
IDBS and Alchemi Partner to Speed Regulatory Filings in Biopharma
IDBS, a cloud‑software provider for the biopharmaceutical sector, and Alchemi, an applied‑AI company, announced a partnership that links Alchemi’s AI agents to data captured in IDBS’s Polar platform. The collaboration is aimed at accelerating the creation of regulatory documents—such as chemistry, manufacturing and controls (CMC) reports, clinical study reports and submission dossiers—by using a single governed data backbone.
Regulatory filings are a long‑standing bottleneck for biopharma companies. CMC teams typically spend months gathering data, drafting reports and reconstructing process histories. Existing AI tools often compromise compliance because they pull data from validated systems, breaking the audit trail. An IDBS spokesperson said that connecting Alchemi’s purpose‑built agents to Polar’s AI‑ready data foundation keeps validated data traceable and auditable.
The Polar platform is a cloud‑based BioPharma Lifecycle Management (BPLM) system that captures data at the point of creation and stores it in a single governed backbone. By feeding this governed data directly into Alchemi’s agents, the system can draft technical reports and submission dossiers at a speed that is “up to 70% faster” than manual processes, according to Alchemi. The agents produce documents that are ready for human‑in‑the‑loop review and sign‑off, maintaining compliance while reducing the time required for regulatory submissions.
Anuj Chadha, co‑founder of Alchemi, explained that the agents draft regulatory filings in minutes while preserving the compliance trail because they work straight from governed data in Polar. Pietro Forgione, general manager of IDBS, added that the partnership enables the company to accelerate critical regulatory milestones using high‑quality, compliant AI agents. He noted that IDBS delivers a governed data backbone that makes AI‑ready data available across the biopharma lifecycle, and that the collaboration with Alchemi supports Danaher’s mission to turn ideas into impact with speed and certainty.
The partnership reflects a broader trend in life‑sciences software, where companies are integrating AI with data governance to meet regulatory requirements. By ensuring that AI agents operate on validated, traceable data, the solution addresses a key concern for regulators: the integrity of the data used to support drug approvals.
At present, the collaboration is focused on enabling faster, compliant drafting of regulatory documents. No public details are available about future product releases, additional AI capabilities, or planned expansions of the partnership. The companies have not disclosed any funding or investment activity related to the collaboration.
In summary, the IDBS‑Alchemi partnership offers a pathway to reduce the time biopharma companies spend on regulatory filings while maintaining compliance. By leveraging a governed data backbone and AI agents that operate within that framework, the solution promises to streamline the preparation of CMC reports, clinical study reports and submission dossiers, potentially saving teams weeks of effort.
Regulatory filings are a long‑standing bottleneck for biopharma companies. CMC teams typically spend months gathering data, drafting reports and reconstructing process histories. Existing AI tools often compromise compliance because they pull data from validated systems, breaking the audit trail. An IDBS spokesperson said that connecting Alchemi’s purpose‑built agents to Polar’s AI‑ready data foundation keeps validated data traceable and auditable.
The Polar platform is a cloud‑based BioPharma Lifecycle Management (BPLM) system that captures data at the point of creation and stores it in a single governed backbone. By feeding this governed data directly into Alchemi’s agents, the system can draft technical reports and submission dossiers at a speed that is “up to 70% faster” than manual processes, according to Alchemi. The agents produce documents that are ready for human‑in‑the‑loop review and sign‑off, maintaining compliance while reducing the time required for regulatory submissions.
Anuj Chadha, co‑founder of Alchemi, explained that the agents draft regulatory filings in minutes while preserving the compliance trail because they work straight from governed data in Polar. Pietro Forgione, general manager of IDBS, added that the partnership enables the company to accelerate critical regulatory milestones using high‑quality, compliant AI agents. He noted that IDBS delivers a governed data backbone that makes AI‑ready data available across the biopharma lifecycle, and that the collaboration with Alchemi supports Danaher’s mission to turn ideas into impact with speed and certainty.
The partnership reflects a broader trend in life‑sciences software, where companies are integrating AI with data governance to meet regulatory requirements. By ensuring that AI agents operate on validated, traceable data, the solution addresses a key concern for regulators: the integrity of the data used to support drug approvals.
At present, the collaboration is focused on enabling faster, compliant drafting of regulatory documents. No public details are available about future product releases, additional AI capabilities, or planned expansions of the partnership. The companies have not disclosed any funding or investment activity related to the collaboration.
In summary, the IDBS‑Alchemi partnership offers a pathway to reduce the time biopharma companies spend on regulatory filings while maintaining compliance. By leveraging a governed data backbone and AI agents that operate within that framework, the solution promises to streamline the preparation of CMC reports, clinical study reports and submission dossiers, potentially saving teams weeks of effort.
